Zacks Small Cap Analysis – AEMD: Progressing & Increasing Scientific & Pre-Scientific Actions in Price Environment friendly Method – Cyber Tech

By M. Marin

NASDAQ:AEMD

READ THE FULL AEMD RESEARCH REPORT

Assessing if the Hemopurifier at the side of customary of care remedy can enhance the inhabitants that may profit from mixed remedy

Aethlon Medical (NASDAQ:AEMD) introduced FY 4Q (quarter ended March 31, 2025) outcomes final week and offered a enterprise replace. The corporate’s major focus presently is on researching lead asset the Hemopurifier® therapeutic blood filtration system as a possible remedy in oncology. AEMD is conducting a basket oncology trial to review the affect of the Hemopurifier in sufferers with varied strong tumors who’ve steady or progressive illness throughout anti-PD-1 monotherapy remedy. Solely about 30% of most cancers sufferers who obtain pembrolizumab (Keytruda^®) or nivolumab (Opdivo^®) remedy for strong tumors have lasting medical responses. The corporate’s speculation is that utilizing the Hemopurifier at the side of remedy of checkpoint inhibitors and / or mixture remedy can enhance the p.c of sufferers who can profit from mixed remedy.

The research is being performed at a number of websites in Australia. The trial is a section 1 security, feasibility and dose-finding research. If the research reveals the Hemopurifier to be helpful in a number of most cancers sorts, the corporate believes the info will help the broad utility of the machine. Furthermore, by specializing in a number of cancers and together with sufferers with quite a lot of strong tumors, the corporate is constructing a database to help regulatory approval.

The primary three sufferers have been handled. Participant #1 was handled with the Hemopurifier on January 29, 2025, for 4 hours on a single day. The affected person tolerated the process with out problems. Contributors #2 and #3 obtained remedy in June 2025. All members accomplished a single 4-hour Hemopurifier remedy with out machine deficiencies or fast problems and have additionally accomplished a 7-day security follow-up.

Furthermore, the research protocol has been expanded to mirror evolving immunotherapy customary of care akin to mixture remedy. The machine can be now additionally being evaluated as a remedy at the side of Keytruda or Opdivo together with different remedy. It is because Keytruda and different remedy are usually not solely used as standalone remedy, however typically utilized in mixture with different therapies.

Preliminary knowledge from 1st cohort probably this month & anticipated to help the Hemopurifier’s potential to scale back tumor-derived EVs & improve T-cell exercise towards tumors

With this protocol modification, the AEMD trial will analyze whether or not the Hemopurifier may also help lower the focus of EVs in most cancers sufferers being handled with varied customary of care approaches and thereby enhance general affected person outcomes. AEMD expects to announce the preliminary knowledge from the primary cohort of sufferers later this month. AEMD anticipates that knowledge from the primary remedy cohort will help the Hemopurifier’s potential skill to scale back tumor-derived EVs and improve T cell exercise towards tumors.

Analysis extends past oncology to Lengthy Covid, different areas

Individually, extreme ranges of PD-EVs (platelet-derived EVs) have been implicated in lots of ailments, together with most cancers, lupus, systemic sclerosis, a number of sclerosis, Alzheimer’s illness, sepsis, acute and Lengthy COVID. The Hemopurifier has been proven to take away EVs in preclinical ex vivo and in addition in sufferers with extreme acute COVID-19 by way of emergency use software. Whereas sustaining inflexible price controls (OpEx declined 26% y/y in FY 25), the corporate continues pre-clinical analysis and evaluation of the Hemopurifier in areas exterior of oncology. For instance, outcomes from a preclinical ex vivo research have been printed in bioRxiv in Might 2025 and reveal that the Hemopurifier eliminated 98.5% of platelet-derived extracellular vesicles (PD-EVs) from human plasma. The outcomes help shifting ahead with the continued oncology research in Australia, launching the same research in India and in addition level to different potential purposes of the Hemopurifier in EV-associated ailments. As well as, Aethlon collaborated with the UCSF Medical Heart to judge plasma samples from members with Lengthy COVID and has had an summary accepted for poster presentation on the Keystone Symposium on Lengthy COVID and Different Submit-Acute An infection Syndromes.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to obtain our articles and experiences emailed on to you every morning. Please go to our web site for extra data on Zacks SCR. 

DISCLOSURE: Zacks SCR has obtained compensation from the issuer straight, from an funding supervisor, or from an investor relations consulting agency, engaged by the issuer, for offering analysis protection for a interval of at least one 12 months. Analysis articles, as seen right here, are a part of the service Zacks SCR offers and Zacks SCR receives quarterly funds totaling a most charge of as much as $40,000 yearly for these companies offered to or relating to the issuer. Full Disclaimer HERE.